GlassScriptPhysician profile
Edgar R Blecker
NPI 1952388100
$9,791.76
in general payments reported to CMS, 2019-2025
35 companies · $670 in 2025
The $670 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,552 · 2020: $1,252 · 2021: $1,792 · 2022: $1,569 · 2023: $1,465 · 2024: $491 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,532 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,532.38 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,724.40 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $1,589.51 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $1,334.95 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $957.11 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $675.74 | 2019-2025 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $564.72 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.88 | 2019-2023 | Tradjenta, Stiolto Respimat |
| Esperion Therapeutics, INC. | $288.54 | 2021-2023 | Nexletol |
| Lilly USA, LLC | $278.60 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $249.49 | 2021-2023 | Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $208.03 | 2020-2023 | Xifaxan |
| Medtronic, INC. | $204.34 | 2021-2024 | Na, Minimed 780g |
| Amarin Pharma, INC. | $137.29 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.05 | 2022 | |
| Astellas Pharma US INC | $117.64 | 2021-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $107.81 | 2019 | |
| Pfizer INC. | $107.25 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $106.33 | 2019 | |
| Mylan Specialty L.P. | $98.24 | 2020-2024 | Yupelri |
| Paratek Pharmaceuticals, INC. | $96.11 | 2023 | Nuzyra |
| Boston Scientific Corporation | $76.62 | 2023 | Rezum Generator |
| Novartis Pharmaceuticals Corporation | $69.64 | 2022 | |
| Insmed, INC. | $53.87 | 2025 | Arikayce |
| Allergan, INC. | $50.73 | 2020 | |
| Eisai INC. | $44.30 | 2024-2025 | |
| Exact Sciences Corporation | $42.00 | 2024 | Cologuard Collection Kit |
| Pulmonx Corporation | $35.29 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Protega Pharmaceutials INC | $24.20 | 2023 | Roxybond |
| Inspire Medical Systems, INC. | $23.01 | 2025 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.26 | 2025 | Caplyta |
| Philips North America LLC | $21.01 | 2024 | (Ak6) Vest Therapy |
| Verona Pharma, INC. | $18.89 | 2025 | Ohtuvayre |
| Xeris Pharmaceuticals, INC. | $18.19 | 2025 | Gvoke Hypopen |
| Dexcom, INC. | $17.48 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Blecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.